Recombinant Human C4.4A/LYPD3 Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 5428-C4
Key Product Details
Product Specifications
Source
Mouse myeloma cell line, NS0-derived human C4.4A/LYPD3 protein
Leu31-His286, with a C-terminal 6-His tag
Leu31-His286, with a C-terminal 6-His tag
Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Leu31
Predicted Molecular Mass
27.7 kDa
SDS-PAGE
60-75 kDa, reducing conditions
Activity
Measured by its binding ability in a functional ELISA.
When rhLYPD3 is immobilized at 0.5 μg/mL (100 μL/well), rhGalectin-3 binds with an apparent KD <80 nM.
When rhLYPD3 is immobilized at 0.5 μg/mL (100 μL/well), rhGalectin-3 binds with an apparent KD <80 nM.
Formulation, Preparation and Storage
5428-C4
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution |
Reconstitute at 100 μg/mL in sterile PBS.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: C4.4A/LYPD3
C4.4A, also known as Ly6/PLAUR domain containing 3 (LYPD-3), is a GPI-linked protein with structural similarity to the urokinase-type plasminogen activator receptor (uPAR) (1). It is a 65 - 100 kDa molecule with variable cell type-specific N- and O-linked glycosylation, and shares 80% amino acid sequence identity with mouse and rat C4.4A (2, 3). Mature human C4.4A contains two uPAR/Ly6 domains and a Ser/Thr/Pro-rich (STP) region that includes a protease sensitive site (4, 5). Proteolytic cleavage following the second uPAR/Ly6 domain generates a 35 - 40 kDa soluble form, while ADAM10 or ADAM17-mediated cleavage within the STP region generates a 90 kDa soluble form (6, 8). Soluble C4.4A can also be shed and released in membrane vesicles (5). C4.4A is expressed in the suprabasal layers of stratified squamous epithelium and is upregulated on migrating keratinocytes during wound healing (6, 7). Its expression is downregulated during the onset of epithelial dysplasia but is subsequently upregulated at the invasive front of melanomas and various carcinomas (2, 6, 5, 9). Metastases derived from these tumors also express high levels of C4.4A (2, 5, 6). The interaction of C4.4A with Laminin 1 and 5 on neighboring cells promotes the adhesion, spreading, and migration of tumor cells (4, 6, 10). C4.4A additionally interacts with Galectin-3 and the anterior gradient proteins AG-2 and AG-3 (10, 11). C4.4A overexpression in non-small cell lung cancer is predictive of increased mortality (12).
References
- Jacobsen, B. and M. Ploug (2008) Curr. Med. Chem. 15:2559.
- Rosel, M. et al. (1998) Oncogene 17:1989.
- Paret, C. et al. (2007) Br. J. Cancer 97:1146.
- Smith, B.A. et al. (2001) Cancer Res. 61:1678.
- Wurfel, J. et al. (2001) Gene 262:35.5.
- Hansen, L.V. et al. (2008) Int. J. Cancer 122:734.
- Hansen, L.V. et al. (2004) Biochem. J. 380:845.
- Esselens, C.W. et al. (2008) Biol. Chem. 389:1075.
- Seiter, S. et al. (2001) J. Invest. Dermatol. 116:344.
- Paret, C. et al. (2005) Int. J. Cancer 115:724.
- Fletcher, G.C. et al. (2003) Br. J. Cancer 88:579.
- Hansen, L.V. et al. (2007) Lung Cancer 58:260.
Long Name
Leucine Rich Repeat and Fibronectin Type III Domain Containing 3
Alternate Names
LYPD3, MIG-C4
Gene Symbol
LYPD3
UniProt
Additional C4.4A/LYPD3 Products
Product Documents for Recombinant Human C4.4A/LYPD3 Protein, CF
Product Specific Notices for Recombinant Human C4.4A/LYPD3 Protein, CF
For research use only
Loading...
Loading...
Loading...